🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Always fun to talk CLL with this crew - looking forward to it! (It was a HUGE ASH for CLL) #cllsm

Acala-BR is approved, which is cool - but wonder when A+V (+/-O) may see approval? m.email.asco.org/nl/jsp/m.jsp?c…

Looking forward to attending this conference - 5 weeks away! #cllsm #MedTwitter

I had a beloved pt of mine not be able to see me today because apparently someone lurking at her dentist’s office tricked her into what sounds like a Medicare advantage plan. So upsetting. 😭 #medtwitter Vincent Rajkumar

Just had a patient screen fail on planned day 1 of a trial because QTcF 471 (protocol requires 470) - how’s your day going? 😭 #medtwitter

Lovely to see this in print - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | New England Journal of Medicine nejm.org/doi/full/10.10…

"Treating Relapse After Initial Therapy: PART 2" is a must-attend session at #NashvilleHeme25! Moderated by Dr. Ronald Tang, this session will feature expert insights from Drs. calliecoombs, Carla Casulo, MD, Jakub Svoboda, and Tycel Phillips (Tycel Phillips) as they dive into

Looking forward to traveling to Nashville next week for this meeting!

Oh boy this debate is going to spicy - excited to see it! Krina Patel Caitlin Costello, MD Rahul Banerjee, MD, FACP Nashville Hematology Conference - Krina in lead so far based on her intro song (who runs the world? Girls!)

Easy vote. Tough part will be if both you and UC Irvine School of Medicine make it to the finals!

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Think about opening EVOLVE (S1925) at your site if you haven’t already! #cllsm

Great analogy - whether to treat SMM is like your political party in our current climate. Most docs are totally decided on what they think is right but it’s the small group of independents they you are trying to sway. (Credit to Pete Voorhees) #HemeDAVA

Better late than never 😏 - great to see in print. I still find it a tough sell to offer an IV treatment to pts who are desiring simplicity of an oral agent, but the benefits are real…

Whoa this is interesting and not something that I had previously considered Martin S. Tallman, MD

I don’t know the right answer on what amount of access is “right” - I definitely can see both sides (I tend to lean to more access but have seen downstream negative effects from this rarely)

45 M. Asymptomatic Inc enl LN in root of mesentry Excisional LN bx shows- grade 3A follucular + potential castelman BM bx neg PET- Isolated LN Tx? Aaron Goodman - “Papa Heme” Oncology Brothers calliecoombs Santhosh Ambika ONCO BRUNO Pallawi Torka Madiha Iqbal MD

Was already a Shingrix fan but this is more info to put the icing on the vaccine cake (though I still think hard to accept if it’s a true causal link) #cllsm

Whoa this is huge! Can’t wait to read

Pleasure to co-chair the rapid oral session with Ann LaCasce, MD - saw some great data. Just like the lights in room E450a, the future is bright for CLL and NHL 😎 #ASCO2025 #ASCO25 Mazyar Shadman, MD MPH